GnRH and LHR gene variants predict adverse outcome in premenopausal breast cancer patients

Breast Cancer Research

Volumn 9, Issue 4, 2007, Pages

  Piersma, Djura ^a   Themmen, Axel P N ^a   Look, Maxime P ^a   Klijn, Jan G M ^a   Foekens, John A ^a   Uitterlinden, André G ^a   Pols, Huibert A P ^a   Berns, Els M J J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; GONADORELIN; SERINE; TRYPTOPHAN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; LUTEINIZING HORMONE RECEPTOR; TAMOXIFEN;

ADULT; ADVERSE OUTCOME; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREMENOPAUSE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RECURRENCE RISK; RISK ASSESSMENT; BREAST TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; MIDDLE AGED; RETROSPECTIVE STUDY; SEGMENTAL MASTECTOMY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; POLYMORPHISM, GENETIC; PREMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, LH; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 36649011022     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1756     Document Type: Article

References (33)

1. Chung M Chang HR Bland KI Wanebo HJ Younger women with breast carcinoma have a poorer prognosis than older women Cancer 1996, 77:97-103 10.1002/ (SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3 8630946
2. Aebi S Gelber S Castiglione-Gertsch M Gelber RD Collins J Thurlimann B Rudenstam CM Lindtner J Crivellari D Cortes-Funes H Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000, 355:1869-1874 10.1016/S0140-6736(00)02292-3 10866443
3. Dellapasqua S Colleoni M Gelber RD Goldhirsch A Adjuvant endocrine therapy for premenopausal women with early breast cancer J Clin Oncol 2005, 23:1736-1750 10.1200/JCO.2005.11.050 15755982
4. SEER Cancer Statistics Review, 1975-2004 http://seer.cancer.gov/csr/ 1975_2004
5. Clemons M Goss P Estrogen and the risk of breast cancer N Engl J Med 2001, 344:276-285 10.1056/NEJM200101253440407 11172156
6. Mitrunen K Hirvonen A Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism Mutat Res 2003, 544:9-41 10.1016/S1383-5742(03)00016-4 12888106
7. Martin AM Weber BL Genetic and hormonal risk factors in breast cancer J Natl Cancer Inst 2000, 92:1126-1135 10.1093/jnci/92.14.1126 10904085
8. Weiss G Skurnick JH Goldsmith LT Santoro NF Park SJ Menopause and hypothalamic-pituitary sensitivity to estrogen JAMA 2004, 292:2991-2996 10.1001/jama.292.24.2991 15613667
9. Landgren BM Collins A Csemiczky G Burger HG Baksheev L Robertson DM Menopause transition: Annual changes in serum hormonal patterns over the menstrual cycle in women during a nine-year period prior to menopause J Clin Endocrinol Metab 2004, 89:2763-2769 10.1210/jc.2003-030824 15181055
10. Powell BL Piersma D Kevenaar ME van Staveren IL Themmen AP Iacopetta BJ Berns EMJJ Luteinizing hormone signaling and breast cancer: polymorphisms and age of onset J Clin Endocrinol Metab 2003, 88:1653-1657 10.1210/jc.2002-021585 12679452
11. Piersma D Berns EMJJ Verhoef-Post M Uitterlinden AG Braakman I Pols HAP Themmen APN A common polymorphism renders the luteinizing hormone receptor protein more active by improving signal peptide function and predicts adverse outcome in breast cancer patients J Clin Endocrinol Metab 2006, 91:1470 -1476 10.1210/jc.2005-2156 16464948
12. Nakayama Y Wondisford FE Lash RW Bale AE Weintraub BD Cutler GB Jr Radovick S Analysis of gonadotropin-releasing hormone gene structure in families with familial central precocious puberty and idiopathic hypogonadotropic hypogonadism J Clin Endocrinol Metab 1990, 70:1233-1238 2186053
13. Iwasaki H Emi M Ezura Y Ishida R Kajita M Kodaira M Yoshida H Suzuki T Hosoi T Inoue S Association of a Trp16Ser variation in the gonadotropin releasing hormone signal peptide with bone mineral density, revealed by SNP-dependent PCR typing Bone 2003 32 185 190 10.1016/ S8756-3282(02)00949-3 12633791
14. Smeets-Goevaers CG Lesusink GL Papapoulos SE Maartens LW Keyzer JJ Weerdenburg JP Beijers LM Zwinderman AH Knottnerus JA Pols HA The prevalence of low bone mineral density in Dutch perimenopausal women: the Eindhoven perimenopausal osteoporosis study Osteoporos Int 1998, 8:404-409 10.1007/s001980050083 9850346
15. Atger M Misrahi M Sar S Le Flem L Dessen P Milgrom E Structure of the human luteinizing hormone-choriogonadotropin receptor gene: Unusual promoter and 5′ non-coding regions Mol Cell Endocrinol 1995 111 113 123 10.1016/0303-7207(95)03557-N 7556872
16. Applied Biosystems http://store.appliedbiosystems.com
17. Sasieni PD From genotypes to genes: Doubling the sample size Biometrics 1997, 53:1253-1261 10.2307/2533494 9423247
18. Kaplan EL Meier P Nonparametric estimation from incomplete observations J Am Stat Assoc 1958, 53:457-481 10.2307/2281868
19. Dean M Approaches to identify genes for complex human diseases: Lessons from Mendelian disorders Hum Mutat 2003, 22:261-274 10.1002/humu.10259 12955713
20. SignalP http://www.cbs.dtu.dk/services/SignalP
21. Gründker C Völker P Schulz KD Emons G Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers Gynecol Oncol 2000, 78:194-202 10.1006/gyno.2000.5863 10926802
22. Mangia A Tommasi S Reshkin SJ Simone G Stea B Schittulli F Paradiso A Gonadotropin releasing hormone receptor expression in primary breast cancer: Comparison of immunohistochemical, radioligand and western blot analyses Oncol Rep 2002, 9:1127-1132 12168084
23. McArdle CA Franklin J Green L Hislop JN Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors J Endocrinol 2002, 173:1-11 10.1677/joe.0.1730001 11927379
24. Günthert AR Gründker C Bongertz T Nagy A Schally AV Emons G Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system Breast Cancer Res Treat 2004, 87:255-264 10.1007/s10549-004-8806-8 15528968
25. Kottler ML Starzec A Carre MC Lagarde JP Martin A Counis R The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer Int J Cancer 1997, 71:595-599 10.1002/(SICI)1097-0215(19970516)71:4<595::AID-IJC14>3.0.CO;2-B 9178813
26. Chen A Kaganovsky E Rahimipour S Ben-Aroya N Okon E Koch Y Two forms of gonadotropin-releasing hormone (GnRH) are expressed in human breast tissue and overexpressed in breast cancer: A putative mechanism for the antiproliferative effect of GnRH by down-regulation of acidic ribosomal phosphoproteins P1 and P2 Cancer Res 2002, 62:1036-1044 11861379
27. Miller WR Scott WN Morris R Fraser HM Sharpe RM Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist Nature 1985, 313:231-233 10.1038/313231a0 2982100
28. Pimstone B Epstein S Hamilton SM LeRoith D Hendricks S Metabolic clearance and plasma half disappearance time of exogenous gonadotropin releasing hormone in normal subjects and in patients with liver disease and chronic renal failure J Clin Endocrinol Metab 1977, 44:356-360 320223
29. Klijn JGM Blamey RW Boccardo F Tominaga T Duchateau L Sylvester R Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials J Clin Oncol 2001, 19:343-353 11208825
30. Klijn JGM Beex LV Mauriac L van Zijl JA Veyret C Wildiers J Jassem J Piccart M Burghouts J Becquart D Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study J Natl Cancer Inst 2000, 92:903-911 10.1093/jnci/92.11.903 10841825
31. Jonat W Pritchard KI Sainsbury R Klijn JG Trends in endocrine therapy and chemotherapy for early breast cancer: A focus on the premenopausal patient J Cancer Res Clin Oncol 2006, 1-12
32. Colozza M de Azambuja E Cardoso F Bernard C Piccart MJ Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era Oncologist 2006 11 111 125 10.1634/theoncologist.11-2-111 16476832
33. Stearns V Schneider B Henry NL Hayes DF Flockhart DA Breast cancer treatment and ovarian failure: Risk factors and emerging genetic determinants Nat Rev Cancer 2006, 6:886-893 10.1038/nrc1992 17036039